IgE disruptor for food allergy with Claude-enabled antibody design [pdf] (divergencelabs.com)

A new study has introduced a groundbreaking IgE disruptor designed using Claude, an AI-driven antibody design tool, to improve treatment options for food allergies affecting around 250 million people globally. Traditional medications like omalizumab (Xolair) target free IgE but fail to efficiently remove IgE already bound to receptors on mast cells, which can lead to severe allergic reactions. The research team developed a biparatopic antibody that combines a disruptor arm to displace IgE from its receptor (FcεRI) and an anchor arm that securely holds the antibody to receptor-bound IgE. Initial testing showed that three newly designed variants outperformed omalizumab in removing IgE, suggesting great potential for clinical impact. This development is significant for the AI/ML community as it showcases the application of computational design in drug development, fundamentally altering how biologic therapies are approached for chronic conditions like food allergies. The study involved a detailed campaign where Claude generated over 11,000 design variations, ultimately identifying 20 functional disruptors with binding affinities ranging from 3.4 to 235 nM. By effectively addressing the shortcomings of existing therapies, the new disruptor could redefine treatment protocols, minimizing the reliance on ongoing IgE management and reducing patient burden significantly.